Gilead Sciences (GILD) is attracting significant investor attention following its strong performance, latest developments and ratings by various brokerages. Stock ratings shifted to
Moderate Buy and
Outperform, signaling confidence among analysts on GILD. There has been notable growth in the company's HIV and Oncology sectors, with their twice-yearly shot effectively preventing 96% of HIV cases in a study. The creation of voluntary licensing agreements with six generic manufacturers for Lenacapavir, their HIV prevention drug, suggests an intent to increase access to this vital healthcare resource in high-incidence, resource-limited countries. TD Cowen, BMO Capital, and Leerink Partners all reiterated their positive ratings of GILD. However, some caution was highlighted due to a decline in their one-year Return on Equity (ROE) and the recent sell-off of shares by insider, Johanna Mercier. Furthermore, GILD's Trodelvy indication in the US has withdrawn due to trial setbacks, and they recently had to recall one lot of its
COVID-19 treatment due to the presence of glass particles.
Gilead Sciences GILD News Analytics from Mon, 29 Apr 2024 07:00:00 GMT to Sat, 26 Oct 2024 09:40:29 GMT -
Rating 6
- Innovation 3
- Information 5
- Rumor -6
